title: ALK-positive primary systemic anaplastic large cell lymphoma with extensive cutaneous manifestation.
authors.forename: Kazuha
authors.initials: K
authors.lastname: Ando
authors.forename: Yasuhiko
authors.initials: Y
authors.lastname: Tamada
authors.forename: Kazuyuki
authors.initials: K
authors.lastname: Shimizu
authors.forename: Yoichi
authors.initials: Y
authors.lastname: Akita
authors.forename: Daisuke
authors.initials: D
authors.lastname: Watanabe
authors.forename: Shigeru
authors.initials: S
authors.lastname: Nakamura
authors.forename: Kazuo
authors.initials: K
authors.lastname: Hara
authors.forename: Yoshinari
authors.initials: Y
authors.lastname: Matsumoto
mesh_terms: D000293:Adolescent; D000328:Adult; D000077548:Anaplastic Lymphoma Kinase; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001706:Biopsy; D005260:Female; D006801:Humans; D017728:Lymphoma, Large-Cell, Anaplastic / Q000188:drug therapy / Q000201:enzymology* / Q000473:pathology; D010778:Photochemotherapy; D011505:Protein-Tyrosine Kinases / Q000032:analysis*; D020794:Receptor Protein-Tyrosine Kinases; D012008:Recurrence; D012867:Skin / Q000473:pathology; D012878:Skin Neoplasms / Q000188:drug therapy / Q000201:enzymology* / Q000473:pathology; D013997:Time Factors; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: C000626173:ALK protein, human; D000077548:Anaplastic Lymphoma Kinase; D011505:Protein-Tyrosine Kinases; D020794:Receptor Protein-Tyrosine Kinases